article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic.

article thumbnail

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

Pharmacy Times

After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects. 5 To me, the highlights of this study go beyond the results themselves.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Real-World Data Suggests Cannabis Use is Associated With Major Adverse Cardiovascular Events

Pharmacy Times

1 Scientific evidence between January 1, 2016, and January 31, 2023, was included in the study. This was assessed by analyzing real-world pharmacoepidemiological data and conducting a systematic review and meta-analysis to further quantify this risk. Subscribe Now!

article thumbnail

J&J eyes prostate cancer label expansion for Akeega

Pharmaceutical Technology

Find out more J&J’s drug is an option for patients where medical or surgical treatment to lower testosterone levels has not worked, and in those who have BRCA 1/2 mutations – a subset of homologous recombination repair (HRR) mutations – in whom chemotherapy is not indicated.

article thumbnail

STAT+: Pharmalittle: We’re reading about chemo drugs failing quality tests, Gavi losing U.S. funding, and more

STAT

… Vital chemotherapy drugs used around the world have failed quality tests, putting cancer patients in more than 100 countries at risk of ineffective treatments and potentially fatal side effects, an investigation by  The Bureau of Investigative Journalism  (TBIJ) reveals. And of course, do keep in touch.

article thumbnail

2nd Hit ID Summit

pharmaphorum

Skip to main content Friday 18 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

STAT

But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world.